Endocrine-Mediated Effects of a Benzophenone-Related Chemical, 2,3,4,4’-Tetrahydroxybenzophenone, Based on Uterotrophic Assay, Hershberger Assay, and Subacute Oral Toxicity Study

Kanji Yamasaki1, Hirokazu Okuda2 and Haruhiko Kikkawa1

1Chemicals Evaluation and Research Institute, Tokyo, Japan
2Japan Bioassay Research Center, Kanagawa, Japan

Abstract

The purpose of this study was to investigate the endocrine-mediated effects of a benzophenone-relative compound, 2,3,4,4’-tetrahydroxybenzophenone, based on the OECD protocols. In the uterotrophic assay, female SD rats were subcutaneously injected with the chemical at doses of 0, 100, 300, and 1,000 mg/kg on each of 3 days from postnatal day 20 to day 22, and the uterine weight of rats given the 300 and 1,000 mg/kg doses of the test chemical increased. In the Hershberger assay, the test chemical was orally administered at doses of 0, 60, 200, and 600 mg/kg/d for at least 28 days, serum T4 values decreased in male rats in the 600 mg/kg group. This suggests a mechanism of action related to the inhibition of thyroid peroxidase. The uterotrophic assay used in this study showed that the chemical has estrogen-agonist properties, however, estrogenic effects were not observed in a 28-day repeated-dose toxicity study. On the other hand, endocrine-mediated effects such as thyroid hormone dysfunction were detected in growing rats based on the results of the OECD test guideline No. 407.

Keywords: 2,3,4,4’-tetrahydroxybenzophenone; Uterotrophic assay; Hershberger assay; Test guideline 407; Rat; Endocrine effects

Introduction

Since it was reported that a considerable number of chemicals may have endocrine-disrupting activity in humans and animals, the Organization for Economic Co-operation and Development (OECD) reviewed the original OECD Test Guideline No. 407 and introduced in vivo screening tests in 2008 to detect endocrine-mediated effects. Endocrine-disrupting effects are one of the important parameters used to assess the risk of chemicals in the REACH program.

Benzophenones are widely used as Ultraviolet (UV) light filters and stabilizers in cosmetics, skin creams, and body lotions and as corrosion inhibitors in building materials, automobile components, and automotive antifreeze cooling systems. Benzophenones have been reported to occur in the environment, and some benzophenones have also been reported to possess estrogenic activity based on uterotrophic and various in vitro assays [1-5]. Recently, effects on steroidogenesis in testicular leydig cells and a reduction in thyroid peroxidase by 2,2’,4,4’-tetrahydroxybenzophenone have been reported [6,7]. On the other hand, 2,3,4,4’-tetrahydroxybenzophenone has also been reported to have potent estrogenic activity in human breast cancer cell line MCF-7 and androgenic activity in rat fibroblast cell line NIH3T3, however, a structurally related 2,3,4,4’-tetrahydroxybenzophenone has no estrogenic and androgenic properties [5]. These facts demonstrated that the endocrine-mediated activity differs among hydrated benzophenones. We therefore subjected 2,3,4,4’-tetrahydroxybenzophenone to an uterotrophic assay, the Hershberger assay and TG 407 assay according to the OECD protocols to investigate whether it has endocrine-mediated effects.

Materials and Methods

The study was performed under Good Laboratory Practice guidelines. Animals were cared for according to the principles outlined in the guide for animal experimentation prepared by The Japanese Association for Laboratory Animal Science.

Uterotrophic Assay

Chemical: The test chemical, 2,3,4,4’-tetrahydroxybenzophenone (CAS No. 31127-54-5, >101.3% pure, Figure 1), was obtained from the Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), and olive oil (Maruishi Pharmaceutical Co., Ltd.) was used as a vehicle.

Animals: Crl: CD (SD) rats, dams and their 13-day-old pups were purchased from Charles River Japan Inc. (Atugi, Japan). The dams and pups were housed in polycarbonate pens until weaning. All pups were weaned at 19 days of age and subsequently individually housed in stainless steel wire-mesh cages throughout the study. The immature rats were weighed, weight-ranked, and assigned randomly to each of the experimental and control groups. Body weight and clinical signs were monitored weekly.

Received May 31, 2012; Accepted July 03, 2012; Published July 05, 2012


Copyright: © 2012 Yamasaki K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
were recorded daily throughout the study. Rats were given free access to automatically dispensed water and a commercial diet (CRF-1, Oriental Yeast Co., Tokyo, Japan). The animal room was maintained at a temperature of 23 ± 2°C and a relative humidity of 55 ± 15%, and it was artificially illuminated with fluorescent light on a 12 h light / dark cycle (0800-2000 h).

**Study design:** The chemical was subcutaneously injected at doses of 100, 300, and 1,000 mg/kg/day into the back of 20-day-old rats on 3 consecutive days. The concentration and stability of the test chemical in the vehicle were confirmed. In 6 rats, ethinyl estradiol (EE, CAS No. 57-63-6, Tokyo Chemical Industry Co., Ltd.) in the vehicle was also subcutaneously injected into the back at a dose of 0.6 µg/kg/day on the same 3 consecutive days after injection of the test chemical at the doses above. The test chemical and EE were dissolved in olive oil as the vehicle. A vehicle control group was injected with olive oil alone, and a positive control group was injected with EE at a dose of 0.6 µg/kg/day. A group injected with the estrogen-antagonist chemical tamoxifen (CAS No. 10540-29-1, MP Biochemicals, Inc.) at a dose of 1 mg/kg/day plus EE was also established to confirm the reliability of this study. Each group consisted of 6 rats. The doses were based on the results of a preliminary study. The animals were killed by bleeding from the abdominal aorta under deep ether anesthesia approximately 24 h after the final dose. At necropsy, the uteri were carefully dissected free of adhering fat and mesentery, and weighed.

**Statistical analysis:** Differences in body weight and organ weight between the vehicle group and each of the chemical groups and between the vehicle-plus-EE group and each of the chemical plus-EE groups were assessed for statistical significance by the two-tailed Student’s t-test.

**Chemical:** The chemical used in this assay was same in used in the uterotrophic assay.

**Animals:** Five-week-old Crl: CD (SD) rats were purchased from Charles River Laboratories Japan, Inc. (Atugi, Japan). Animals were weighed, weight-ranked, and randomly assigned to each of the treatment groups and control group before administration. After the animals were housed individually in stainless steel, wire-mesh cages throughout the study. Rats were provided with water automatically and with a commercial diet (CRF-1, Oriental Yeast Co., Tokyo, Japan) ad libitum. Other housing conditions were essentially the same as for the uterotrophic assay.

**Study design:** Rats were orally gavaged with 0, 60, 200 and 600 mg/kg/day of test chemical. These doses were selected on the basis of a preliminary test in which rats were orally gavaged with 0, 30, 100, 300 and 1,000 mg/kg/day of test chemical for 14 days, with result that some toxic effects such as reduced body weight gains, reduced hemoglobin values, increased platelet counts, increased alanine aminotransferase values and reduced thymus weights were detected in the 1,000 mg/kg group. A vehicle control group was gavaged with olive oil (using 5 ml/kg of olive oil containing the test chemical) and the concentration and stability of the test chemical in the vehicle were confirmed before use. Each group consisted of 10 males and 10 females. Animals were killed by exsanguinations under ether anesthesia, and blood samples were obtained from the abdominal aorta and examined for hematological parameters, clinical biochemistry and hormonal parameters. In addition to the requirements of the current OECD Test Guideline 407, we also adopted hormone analysis, estrous cycling and spermatology as optional endpoints.

**General observations:** Clinical signs were recorded daily. Once before the first dose and once a week thereafter, detailed clinical observations of all animals were made outside the home cage. The signs for which the animals were examined included changes in skin, fur, eyes, and mucous membranes, frequency of urine and feces, and autonomic activity (e.g. lacrimation, piloerection, pupil size, respiratory pattern). Changes in gait, posture, response to handling, the occurrence of clonic or tonic movements, stereotypes (e.g. excessive grooming, circling), or bizarre behavior (e.g. self-mutilation, walking backwards), were also recorded. In the 4th week, a functional observation battery (FOB) that tested sensory reactivity to stimuli of different types (e.g. auditory, visual, and proprioceptive), assessed grip strength, and assessed motor activity, was also conducted.

**Body weight and food consumption:** Individual body weight was recorded twice weekly and immediately before necropsy. Food consumption was measured weekly.

**Hematology:** The following were examined in the hematological examinations: red blood cell count, white blood cell count, hemoglobin concentration, hematocrit value, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, prothrombin time, activated partial thromboplastin time, and differential leukocyte count.

**Clinical biochemistry:** Serum levels of the following were measured in the clinical biochemistry examination: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase, total protein, albumin, globulin, urea, creatinine, total cholesterol, HDL cholesterol, triglycerides, and uric acid.
The following organs were fixed in 10% neutral buffered formalin and examined: prostate, seminal vesicles, ovaries, and testes, epididymides, seminal vesicles, prostate (ventral and dorsolateral lobes), ovaries, uterus, adrenals, liver, spleen, kidneys, heart, brain, and thymus, as fresh organs, and the ventral prostate, dorsolateral prostate, thyroid and pituitary gland, after organ fixation. The ovaries, uterus and thymus, as fresh organs, and the ventral prostate, dorsolateral prostate, epididymides, seminal vesicles, prostate (ventral and dorsolateral lobes), and epididymides and testes were fixed in Bouin’s solution before examining them. In the present study, we did not examine the following organs listed in the current OECD Test Guideline 407 because we focused on the changes in endocrine-related organs: stomach, intestine, urinary bladder, eye ball, Harderian gland, sciotic nerve and spinal cord.

Statistical analysis: Bartlett’s variance test was performed for the parametric data (Body weight, food consumption, hematological data, clinical biochemical data, hormonal data, organ weight, grip strength and locomotor activity). Bartlett’s test revealed a homogeneous variance, so one-way analysis of variance was conducted and if the result of the one-way analysis was significant, Dunnett’s test was performed to compare the comparison between the treated and the control groups.

Data with an inhomogeneous variance shown by Bartlett’s test, or non-parametric data (FOB numerical data: the number of stools, the number of urinary pools and incidence rate of abnormal spermatozoa) was subjected to Kruskal-Wallis’ rank test, and if a significant difference was observed, Dunnett’s approach was carried out. Incidence rate of abnormal estrous cycles and histopathological changes were analyzed by the Fisher’s exact probability test and Chi-square test, respectively. In the evaluation of the results, when a difference from the control was found at a significance level of 1% or 5%, it was regarded as a significant change.

Results

Uterotrophic assay

Clinical signs and body weight: No abnormal clinical findings were detected in the rats given the test chemical. A decrease in body weight gains was found in the 1,000 mg/kg group (Table 1).

Uterine weight: Uterine wet weight, blotted weight, and relative weight increased in the 300 and 1,000 mg/kg groups (Table 1). The wet, blotted, and relative weights of the uteri of rats given EE increased compared to the rats given vehicle alone, and the uterine weights of rats given tamoxifen plus EE decreased compared to the rats given EE alone.

Hershberger assay

Clinical signs and body weight: No abnormal clinical findings or body weight changes were detected in the rats given the test chemical (Table 2).

Organ weight: No dose-dependent changes were detected in any of the accessory sex organs (Table 2). The organ weight of all accessory sex organs of the rats given TP increased compared to the rats given vehicle alone, and the organ weights of the rats given flutamide plus TP were decreased compared to the rats given TP alone.

TG 407

Body weight and food consumption: The changes in body weight are shown in Table 3. A decrease in body weight gains was found in the 600 mg/kg group of both sexes, accompanied by decreased food consumption.

General observations: Grip strength changes and locomotor

Table 1: Body weights and uterine weights (mean ± SD) in the uterotrophic assay.

<table>
<thead>
<tr>
<th>Dosages (mg/kg/d)</th>
<th>Body weight (g)</th>
<th>Uterine wet weight</th>
<th>Uterine blotted weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absolute (mg)</td>
<td>Relative (mg/100g)</td>
<td>Absolute (mg)</td>
</tr>
<tr>
<td>0</td>
<td>66.2 ± 3.3</td>
<td>48.5 ± 3.4</td>
<td>73.3 ± 4.6</td>
</tr>
<tr>
<td>100</td>
<td>65.2 ± 2.7</td>
<td>58.7 ± 11.1</td>
<td>90.2 ± 18.4</td>
</tr>
<tr>
<td>300</td>
<td>66.2 ± 3.9</td>
<td>75.4 ± 14.9*</td>
<td>112.6 ± 21.5*</td>
</tr>
<tr>
<td>1,000</td>
<td>61.9 ± 2.4†</td>
<td>170.3 ± 25.2*</td>
<td>276.7 ± 50.7†</td>
</tr>
<tr>
<td>EE</td>
<td>64.8 ± 2.4</td>
<td>176.2 ± 30.1</td>
<td>272.2 ± 46.9</td>
</tr>
<tr>
<td>100+EE</td>
<td>64.4 ± 4.2</td>
<td>161.3 ± 36.5</td>
<td>252.4 ± 66.6</td>
</tr>
<tr>
<td>300+EE</td>
<td>65.0 ± 2.5</td>
<td>146.4 ± 31.6</td>
<td>222.6 ± 49.6</td>
</tr>
<tr>
<td>1,000+EE</td>
<td>62.3 ± 3.2</td>
<td>190.8 ± 40.4</td>
<td>305.9 ± 62.3</td>
</tr>
<tr>
<td>TMX+EE</td>
<td>63.2 ± 3.6</td>
<td>110.4 ± 11.8**</td>
<td>174.5 ± 12.5**</td>
</tr>
</tbody>
</table>
activities are shown in Table 4. Forelimb grip strength was reduced in male rats in the 200 and 600 mg/kg groups, but no abnormal locomotor activities were observed in any male groups. No significant abnormalities were observed in any of the female rat groups.

Hematological and clinical biochemical findings: Abnormal hematological and clinical biochemical findings are shown in Table 5. In male rats, triglyceride values decreased, and alanine aminotransferase values and A/G ratio increased in the 600 mg/kg group. In female rats, hemoglobin, hematocrit, glucose, total cholesterol, triglyceride, and phospholipid values decreased in the 200 and/or 600 mg/kg groups, and total bilirubin values and A/G ratio increased in the 600 mg/kg group.

Hormonal findings: Hormonal findings are shown in Table 6. Serum T4 values decreased significantly in male rats in the 600 mg/kg group. TSH values increased in male rats in the 200 mg/kg group, but no changes were observed in the 600 mg/kg group.

Organ weights: Changes in organ weights are shown in Table 3. In male rats, the relative weights of the kidney and brain increased in the 600 mg/kg group. In female rats, the relative weights of the brain increased in the 600 mg/kg group.

Estrous cycling, Sperm analysis, and Gross morphological and Histopathological findings
No abnormalities were detected in any of the groups.
Discussion

This study was conducted to investigate the endocrine-mediated effects of 2,3,4,4'-tetrahydroxybenzophenone in accordance with OECD Test Guidelines.

In the uterotrophic assay the uterine weight of rats given EE was higher than in rats given the vehicle alone, and the organ weights of the rats given tamoxifen plus EE were lower than in the rats given EE alone, and in the Hershberger assay the weights of the accessory sex organ of rats given TP were higher than in rats given the vehicle alone, and the organ weights of rats given flutamide plus TP were lower than in rats given TP alone, thereby confirming the reliability of the uterotrophic and Hershberger assays used in this study. The uterine weight of the rats given the 300 and 1,000 mg/kg doses of the test chemical was not apparent in rats given 100 mg/kg in the uterotrophic assay. We observed changes in serum TSH values when the estrogenic effects of 2,3,4,4'-tetrahydroxybenzophenone were not detected at a dose of 600 mg/kg under OECD test guideline No. 407 [10,11]. These findings demonstrated the absence of any estrogenic effects of some chemicals using bisphenol A-related compounds revealed that estrogenic effects such as abnormal estrous cycles, reduced male accessory sex organ weights and histopathological abnormalities in the sex and accessory sex organs appeared when high estrogenic potency was confirmed by the OECD Test Guideline No. 407 [1,17].

In a study using ovariectomized rats [14], it was reported that 2,2',4,4'-tetrahydroxybenzophenone was associated with decreased T4 values and increased TSH values without changes in T3 values, and it has been suggested that this compound and benzophenone affect thyroid hormone homeostasis by inhibiting or inactivating thyroid peroxidase [7,14]. The changes in serum T4 values seen in this study appear to be due to the effects of thyroid peroxidase as well as other benzophenone-related compounds. The fact that serum TSH values did not change may be related to the degree to which T4 values decreased.

The estrogenic properties of ethinyl estradiol were detected at a dose of 2–3 μg/kg in the uterotrophic assay [1,15,16], and estrogenic effects were observed starting at 10–50 μg/kg, under OECD test guideline No. 407 [1,17]. In contrast, in the uterotrophic assay, bisphenol A's estrogenic properties were detected at a dose of 20 mg/kg and abnormal estrous stages were only observed at a dose of 600 mg/kg in OECD test guideline No. 407 [18]. On the other hand, the uterotrophic properties of genistein and nonylphenol were detected at doses of 20–60 mg/kg and 20–75 mg/kg, respectively [16], and the estrogenic effects were not apparent in rats given 1,000 mg/kg of genistein or 300 mg/kg of nonylphenol in OECD test guideline No. 407 [10,11]. These findings demonstrated the absence of any estrogenic effects of some chemicals using bisphenol A-related compounds revealed that estrogenic effects such as abnormal estrous cycles, reduced male accessory sex organ weights and histopathological abnormalities in the sex and accessory sex organs appeared when high estrogenic potency was confirmed by the OECD Test Guideline No. 407 [19,20]. In the present study, the estrogenic effects of 2,3,4,4'-tetrahydroxybenzophenone were not detected at a dose of 600 mg/kg under OECD test guideline No. 407, and its estrogenic properties were not apparent in rats given 100 mg/kg in the uterotrophic assay. We

<p>| Table 5: Abnormal hematological and clinical biochemical values (mean ± SD) in the TG 407. |</p>
<table>
<thead>
<tr>
<th>Items</th>
<th>Control</th>
<th>60mg/kg/day</th>
<th>200mg/kg/day</th>
<th>600mg/kg/day</th>
<th>Control</th>
<th>60mg/kg/day</th>
<th>200mg/kg/day</th>
<th>600mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>15.8 ± 0.4</td>
<td>15.8 ± 0.4</td>
<td>15.6 ± 0.5</td>
<td>15.6 ± 0.5</td>
<td>14.7 ± 0.4</td>
<td>14.6 ± 0.7</td>
<td>14.2 ± 0.5</td>
<td>14.0 ± 0.4*</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>41.6 ± 1.1</td>
<td>41.8 ± 1.5</td>
<td>41.0 ± 1.3</td>
<td>41.3 ± 1.2</td>
<td>38.6 ± 1.3</td>
<td>38.6 ± 2.0</td>
<td>37.1 ± 1.2</td>
<td>37.0 ± 1.2*</td>
</tr>
<tr>
<td>T-Bil (μmol/l)</td>
<td>0.12 ± 0.02</td>
<td>0.12 ± 0.01</td>
<td>0.13 ± 0.01</td>
<td>0.13 ± 0.02</td>
<td>0.11 ± 0.01</td>
<td>0.11 ± 0.01</td>
<td>0.11 ± 0.01</td>
<td>0.13 ± 0.01*</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>185 ± 10</td>
<td>182 ± 16</td>
<td>186 ± 10</td>
<td>180 ± 10</td>
<td>198 ± 15</td>
<td>189 ± 12</td>
<td>194 ± 10</td>
<td>181 ± 14*</td>
</tr>
<tr>
<td>T-Chol (mg/dl)</td>
<td>66 ± 11</td>
<td>69 ± 12</td>
<td>63 ± 9</td>
<td>63 ± 7</td>
<td>68 ± 9</td>
<td>64 ± 12</td>
<td>60 ± 8</td>
<td>52 ± 10*</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>91 ± 42</td>
<td>97 ± 45</td>
<td>75 ± 34</td>
<td>40 ± 14*</td>
<td>77 ± 41</td>
<td>80 ± 36</td>
<td>45 ± 17</td>
<td>36 ± 12*</td>
</tr>
<tr>
<td>Phospholipid (mg/dl)</td>
<td>129 ± 9</td>
<td>137 ± 19</td>
<td>125 ± 10</td>
<td>121 ± 12</td>
<td>150 ± 20</td>
<td>143 ± 19</td>
<td>131 ± 12</td>
<td>119 ± 16*</td>
</tr>
<tr>
<td>ALT (IU/ℓ)</td>
<td>35 ± 4</td>
<td>34 ± 5</td>
<td>32 ± 5</td>
<td>38 ± 5*</td>
<td>30 ± 5</td>
<td>29 ± 5</td>
<td>27 ± 3</td>
<td>32 ± 3</td>
</tr>
<tr>
<td>A/G ratio</td>
<td>1.4 ± 0.1</td>
<td>1.4 ± 0.1</td>
<td>1.4 ± 0.1</td>
<td>1.5 ± 0.1*</td>
<td>1.6 ± 0.2</td>
<td>1.7 ± 0.2</td>
<td>1.8 ± 0.2</td>
<td>2.0 ± 0.2*</td>
</tr>
</tbody>
</table>

<p>| Table 6: Hormonal values (mean ± SD) in the TG 407. |</p>
<table>
<thead>
<tr>
<th>Items</th>
<th>Control</th>
<th>60mg/kg/day</th>
<th>200mg/kg/day</th>
<th>600mg/kg/day</th>
<th>Control</th>
<th>60mg/kg/day</th>
<th>200mg/kg/day</th>
<th>600mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>T3 (ng/dl)</td>
<td>2.4 ± 0.3</td>
<td>2.5 ± 0.3</td>
<td>2.2 ± 0.3</td>
<td>2.2 ± 0.3</td>
<td>2.4 ± 0.3</td>
<td>2.5 ± 0.2</td>
<td>2.4 ± 0.2</td>
<td>2.5 ± 0.3</td>
</tr>
<tr>
<td>T4 (ng/ml)</td>
<td>89.6 ± 16.0</td>
<td>99.2 ± 20.4</td>
<td>86.4 ± 13.1</td>
<td>71.8 ± 11.0*</td>
<td>67.7 ± 10.9</td>
<td>73.8 ± 9.3</td>
<td>71.5 ± 8.2</td>
<td>62.3 ± 7.4</td>
</tr>
<tr>
<td>TSH (ng/ml)</td>
<td>1.8 ± 0.8</td>
<td>2.6 ± 1.8</td>
<td>3.8 ± 2.2*</td>
<td>1.4 ± 0.7</td>
<td>0.7 ± 0.3</td>
<td>1.3 ± 0.6</td>
<td>0.9 ± 0.3</td>
<td>0.8 ± 0.2</td>
</tr>
<tr>
<td>FSH (ng/ml)</td>
<td>3.3 ± 1.0</td>
<td>3.2 ± 1.2</td>
<td>3.6 ± 1.0</td>
<td>3.7 ± 0.7</td>
<td>0.7 ± 0.2</td>
<td>0.8 ± 0.3</td>
<td>1.2 ± 1.0</td>
<td>0.9 ± 0.3</td>
</tr>
<tr>
<td>Testosterone (ng/ml)</td>
<td>1.7 ± 1.4</td>
<td>3.3 ± 2.3</td>
<td>3.0 ± 3.4</td>
<td>2.4 ± 2.0</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Estradiol (pg/ml)</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>23.6 ± 4.4</td>
<td>24.1 ± 3.6</td>
<td>23.0 ± 3.1</td>
<td>22.0 ± 3.5</td>
</tr>
</tbody>
</table>

NE: not examined.
* Significantly different from control at P<0.05.
** Significantly different from control at P<0.01.

believe that estrogenic effects of the present chemical were not detected because its estrogenic properties, as assessed in the uterotrophic assay, are weak.

Reduced body weight gains, hematological effects, and hepatic and renal abnormalities have been reported in 28-day and 14-week repeated-dose toxicity studies of benzophenone [21]. In this study, reduced body weight gains were detected in the 600 mg/kg group of both sexes, and this change was probably an adverse effect caused by this compound. Slightly reduced hemoglobin and hematocrit values, and increased alanine aminotransferase and total bilirubin values were detected in the 600 mg/kg group of male and/or female rats. In the preliminary test, reduced hemoglobin values, increased platelet counts and increased alanine aminotransferase values were also detected in the 1,000 mg/kg group. Therefore, this compound was considered to have the potential to cause hematological and hepatic disorders. Other abnormal parameters found in the clinical biochemical examination and organ weight changes could be related to reduced body weight gains. On the other hand, reduced forelimb grip strength was observed in male rats in the 200 and 600 mg/kg groups. Unfortunately, histopathological examination of the peripheral nerves and muscles around the forelimbs and spinal cord in the thoracic region was not performed in this study. However, no locomotor abnormalities were detected in these groups and similar reduced grip strengths have not been reported in the repeated-dose toxicity studies using benzophenone and related compounds [2,3,5,21,22]. In addition, it has been reported that changes in grip strength are associated with locomotor abnormalities in rats given a number of neurotoxic compounds [23-28]. The mechanisms underlying reduced grip strength in this study were unclear and we could not determine if this change was an adverse effect. The no observed adverse effect level (NOAEL) for this chemical was estimated to be 200 mg/kg/day.

Conclusion

We performed a uterotrophic assay, Hershberger assay, and TG 407 assay of 2,3,4,4′-tetrahydroxybenzophenone according to the OECD protocols in order to investigate its endocrine-mediated effects. Estrogen-agonist properties were detected in the uterotrophic assay, and serum T4 values decreased in the TG 407 protocol by gavage for 4 weeks using propylthiouracil and tamoxifen. Toxicol Lett 144: 195-204.


immunologic effects of exposure to corticosterone, chlorpyrifos, and multiple
doses of tri-ortho-tolyl phosphate over a 28-day period in rats. J Toxicol Environ
Health A 67: 431-457.

neurodevelopmental effects on rats exposed prenatally to sulfentrazone.

Characterization of developmental neurotoxicity of As, Cd, and Pb mixture:
synergistic action of metal mixture in glial and neuronal functions. Toxicol Sci
118: 586-601.